[industry trends of pharmaceutical network] frequent policy, medical insurance fee control and industry upheaval are the consensus of all pharmaceutical people in recent years
War "epidemic": five big mountains for the development of pharmaceutical industry in 2020
Time of Update: 2020-02-17
First of all, conclusion: at the company level, under the current situation of survival of the fittest, what local pharmaceutical companies need to do is still to accelerate
War "epidemic": five big mountains for the development of pharmaceutical industry in 2020
Time of Update: 2020-02-17
First of all, conclusion: at the company level, under the current situation of survival of the fittest, what local pharmaceutical companies need to do is still to accelerate
A pharmaceutical giant plans to close its UK plant and cut 400 jobs
Time of Update: 2020-02-14
Like Novartis, there are not a few pharmaceutical companies that have made layoffs in recent years due to the divestiture of non core businesses.
Kit's car-t therapy is qualified for priority review
Time of Update: 2020-02-11
Today, kit, a subsidiary of Gilead Sciences, announced that the US FDA has accepted its biological product licensing application (BLA) for car-t therapy kte-x19 to treat patients with relapsed / refractory mantle cell lymphoma (MCL).
In 2019, three M & A cases of pharmaceutical enterprises with a transaction value of more than 1 billion
Time of Update: 2020-02-07
[industry trends of pharmaceutical network] in 2019, with the promotion of policies such as the nationwide spread of volume procurement, the dynamic adjustment of medical insurance
Industry reshuffle intensified, and pharmaceutical companies began to break through
Time of Update: 2020-01-30
In recent years, the action of drug companies selling assets and focusing on core business has become more and more frequent.
Forecast of the development trend of biomedical industry in 2020
Time of Update: 2020-01-17
According to Frost & Sullivan report, the market size of monoclonal antibody in China has increased from 3.5 billion yuan in 2012 to 9.1 billion yuan in 2016, with a compound annual growth rate of 26.8%.
Forecast of the development trend of biomedical field in 2020
Time of Update: 2020-01-16
In the past, investors believed that small pharmaceutical companies would invest too much time and resources in R & D stage, and doubted the production problems of new drugs after they went on the market.
Forecast of the development trend of biomedical field in 2020
Time of Update: 2020-01-16
In the past, investors believed that small pharmaceutical companies would invest too much time and resources in R & D stage, and doubted the production problems of new drugs after they went on the market.
Policy year pharmaceutical enterprises deeply affected
Time of Update: 2020-01-14
Recently, Jiangsu Provincial Drug Administration announced that Yangzhou Pharmaceutical was incorporated by Jiangsu Lianhuan pharmaceutical industry
It is understood
Revenue reached 13.4 billion yuan, up 20.7% year on year. What drove the performance of Cr 39 to soar
Time of Update: 2020-01-14
Self diagnosis and treatment business, prescription medicine business and two core business sectors jointly promote the company's products are mostly exclusive or high market share drugs, mainly involving the fields of cold, gastrointestinal diseases, cardiovascular and cerebrovascular diseases, tumors, etc.
Why are large-scale mergers and acquisitions of global pharmaceutical enterprises continuing in 2019
Time of Update: 2020-01-13
In recent years, the market scale of anti-tumor drugs has been expanding.
The official logo of the State Medical Security Bureau is enabled
Time of Update: 2020-01-13
1. Logo, logo pattern and meaning (1) logo pattern and meaning official logo of China Medical Security.Jpg pattern shape: font plus text pattern color: 1.CHS font is blue.
In 2019, the cancer sector fell to the top of round a financing, and the IPO market continued to heat up
Time of Update: 2020-01-13
▲ IPO companies with a market value of more than US $1 billion at the end of 2015-2019 (picture source: reference [2]) SVB's report predicts that investment in biomedicine could fall by 10% - 15% in 2020.
The future of Pharmaceutical Enterprises -- merger and acquisition
Time of Update: 2020-01-13
1, background 2
The driving force of M & A 3
Case analysis: Geely's way of M & a development 4
Comparison of M & A transactions
Cro industry ushers in the golden development period, these enterprises deserve attention
Time of Update: 2020-01-10
[pharmaceutical network market analysis] recently, Zhaoyan new drug released the notice of increase in performance in 2019, which said that it is expected to realize the non net
